Tags

Type your tag names separated by a space and hit enter

Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient.
Nephrol Dial Transplant 2010; 25(8):2792-5ND

Abstract

Hepatitis E virus (HEV) can induce chronic hepatitis in immunosuppressed patients. There is no established treatment for HEV infection. Pegylated interferon-alpha-2a (Peg-IFN-alpha-2a) has been successfully used for treating HEV infection in liver transplant patients with chronic hepatitis. A kidney transplant patient with chronic HEV infection evolved to end-stage kidney disease and started haemodialysis. Three months after immunosuppressive therapy was stopped, HEV RNA was still detected both in serum and in stools. Before considering a retransplantation, we decided to initiate Peg-IFN-alpha-2a therapy to eradicate the virus. A 3-month course of Peg-IFN-alpha-2a was scheduled, and the latter was started at the weekly dose of 135 microg. Serum HEV RNA became negative by Week 3 of Peg-IFN-alpha-2a therapy, and remained negative until the last follow-up, i.e. 6 months after anti-viral therapy was stopped. Hence, we report the first known case of a 3-month course of Peg-IFN-alpha-2a inducing a sustained virological response in this HEV-positive and RNA-positive haemodialysis patient who had failed to be cleared of the virus after immunosuppressant withdrawal.

Authors+Show Affiliations

Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, 1 avenue Jean Poulhès, TSA 50032, Toulouse Cedex 9, France. kamar.n@chu-toulouse.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

20494897

Citation

Kamar, Nassim, et al. "Three-month Pegylated Interferon-alpha-2a Therapy for Chronic Hepatitis E Virus Infection in a Haemodialysis Patient." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 25, no. 8, 2010, pp. 2792-5.
Kamar N, Abravanel F, Garrouste C, et al. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol Dial Transplant. 2010;25(8):2792-5.
Kamar, N., Abravanel, F., Garrouste, C., Cardeau-Desangles, I., Mansuy, J. M., Weclawiak, H., ... Rostaing, L. (2010). Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 25(8), pp. 2792-5. doi:10.1093/ndt/gfq282.
Kamar N, et al. Three-month Pegylated Interferon-alpha-2a Therapy for Chronic Hepatitis E Virus Infection in a Haemodialysis Patient. Nephrol Dial Transplant. 2010;25(8):2792-5. PubMed PMID: 20494897.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. AU - Kamar,Nassim, AU - Abravanel,Florence, AU - Garrouste,Cyril, AU - Cardeau-Desangles,Isabelle, AU - Mansuy,Jean Michel, AU - Weclawiak,Hugo, AU - Izopet,Jacques, AU - Rostaing,Lionel, Y1 - 2010/05/20/ PY - 2010/5/25/entrez PY - 2010/5/25/pubmed PY - 2010/10/29/medline SP - 2792 EP - 5 JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association JO - Nephrol. Dial. Transplant. VL - 25 IS - 8 N2 - Hepatitis E virus (HEV) can induce chronic hepatitis in immunosuppressed patients. There is no established treatment for HEV infection. Pegylated interferon-alpha-2a (Peg-IFN-alpha-2a) has been successfully used for treating HEV infection in liver transplant patients with chronic hepatitis. A kidney transplant patient with chronic HEV infection evolved to end-stage kidney disease and started haemodialysis. Three months after immunosuppressive therapy was stopped, HEV RNA was still detected both in serum and in stools. Before considering a retransplantation, we decided to initiate Peg-IFN-alpha-2a therapy to eradicate the virus. A 3-month course of Peg-IFN-alpha-2a was scheduled, and the latter was started at the weekly dose of 135 microg. Serum HEV RNA became negative by Week 3 of Peg-IFN-alpha-2a therapy, and remained negative until the last follow-up, i.e. 6 months after anti-viral therapy was stopped. Hence, we report the first known case of a 3-month course of Peg-IFN-alpha-2a inducing a sustained virological response in this HEV-positive and RNA-positive haemodialysis patient who had failed to be cleared of the virus after immunosuppressant withdrawal. SN - 1460-2385 UR - https://www.unboundmedicine.com/medline/citation/20494897/Three_month_pegylated_interferon_alpha_2a_therapy_for_chronic_hepatitis_E_virus_infection_in_a_haemodialysis_patient_ L2 - https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfq282 DB - PRIME DP - Unbound Medicine ER -